Once-daily rasagiline, an investigational selective and potent monoamine oxidase type B (MAO-B) inhibitor, is superior to placebo and as effective as entacapone in reducing 'off' time in levodopa-treated patients with advanced Parkinson's disease (PD) and motor fluctuations. This result and other data from the multinational, randomised, double-blind LARGO study were presented at the 56th Annual Meeting of the American Academy of Neurology [San Francisco, US; April−May 2004]. In addition, results from an ancillary study of the LARGO study showed that rasagiline significantly improves freezing of gait (FOG) in this patient group. "We continue to be excited about the potential for rasagiline to help people living with Parkinson's disease", said Dr Rivka Riven Kreitman, vice president of Innovative R&D with Teva Neuroscience. The results of the ancillary study showed that "rasagiline significantly improved one of the most troublesome and limiting symptoms in advanced PD".